Evofem Biosciences, Inc. 8-K

What Happened
Evofem Biosciences, Inc. announced a Fourth Amendment, dated April 10, 2026, to its October 14, 2020 Securities Purchase Agreement with Adjuvant Global Health Technology Fund, L.P. and Adjuvant Global Health Technology Fund DE, L.P. The amendment updates terms for certain convertible promissory notes purchased by Adjuvant, including a revised Maturity Date and restrictions on prepayment.

Key Details

• Parties: Evofem Biosciences and Adjuvant Global Health Technology Fund, L.P. and Adjuvant Global Health Technology Fund DE, L.P.
• Amendment date: April 10, 2026; 8-K filed April 16, 2026.
• New Maturity Date: the earlier of (a) six months after the Effective Date, (b) at Adjuvant’s election, the date of consummation of a Change of Control, or (c) the date of any acceleration per the agreement.
• Prepayment restriction: Notes may not be prepaid prior to six months after the Effective Date without Adjuvant’s prior written consent.

Why It Matters
The amendment changes when the convertible notes must be repaid and limits Evofem’s ability to prepay those notes for at least six months after the Effective Date, which affects the company’s near-term debt obligations and financing flexibility. Adjuvant’s ability to accelerate payment upon a change of control also affects the timing of any repayment or restructuring tied to corporate transactions. Investors should note these contract changes when assessing Evofem’s short-term liquidity and capital structure.